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Abstract  
Objectives 
The aim of this study was to explore the relationships between nausea and vomiting in 
pregnancy and (a): fetal growth restriction; and (b) maternal caffeine metabolism and 
fetal growth restriction. 
 
Methods 
A cohort of 2643 pregnant women, aged 18-45 years, attending two UK maternity units 
between 8-12 weeks gestation, was recruited.  A validated tool assessed caffeine intake at 
different stages of pregnancy and caffeine metabolism was assessed from a caffeine 
challenge test.  Experience of nausea and vomiting of pregnancy was self-reported for 
each trimester.  Adjustment was made for confounders, including salivary cotinine as a 
biomarker of current smoking status.  
 
Results 
There were no significant associations between fetal growth restriction and nausea and 
vomiting in pregnancy, even after adjustment for smoking and alcohol intake.  There 
were no significant differences in the relationship between caffeine intake and fetal 
growth restriction between those experiencing symptoms of nausea and vomiting and 
those who did not, for either the first (p=0.50) or second trimester (p=0.61) after 
adjustment for smoking, alcohol intake and caffeine half-life.  There were also no 
significant differences in the relationship between caffeine half-life and fetal growth 
restriction between those experiencing symptoms of nausea and vomiting and those who 
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did not, for either the first trimester (p=0.91) or the second trimester (p=0.45) after 
adjusting for smoking, alcohol intake and caffeine intake. 
 
Conclusion 
The results from this study show no evidence that the relationship between maternal 
caffeine intake and fetal growth restriction is modified by nausea and vomiting in 
pregnancy. 
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Introduction 
Just two weeks after fertilisation, nausea and vomiting may be the first symptoms of 
pregnancy and reports show that 69 to 89% of women may experience these symptoms 
during this dynamic stage of the lifecycle [1-4].  Although a common symptom, its exact 
aetiology is unknown.  Nausea and vomiting of pregnancy are thought to have a positive 
effect on pregnancy by: ensuring an optimum balance of nutrition between maternal and 
fetal tissues [5]; causing avoidance of foods which may harm the mother or embryos [6]; 
or reflecting a favourable balance of hormones [7].  Timing of nausea and vomiting in 
pregnancy is of particular interest as while food restriction (which coincides with nausea 
and vomiting in pregnancy) during the first trimester may be beneficial to the developing 
fetus, this may not be the case later in pregnancy [5, 8]. 
There have been several studies of the role of nausea in pregnancy and its 
interaction with alcohol, caffeine and smoking [4, 9, 10].  Caffeine, in particular, has 
received much interest in recent years.  Studies have shown that maternal caffeine 
consumption may increase the risk of adverse pregnancy outcomes [11-15].   It has been 
suggested that women who experience nausea may be less likely to consume caffeine 
[16].   The secretion of human chorionic gonadotrophin, which has been suggested as the 
most likely cause of nausea and vomiting in pregnancy [17], has been negatively 
associated with coffee consumption [18, 19].  It is therefore postulated that unchanged or 
heavy caffeine consumption may be a marker of suboptimal placental hormone synthesis 
[7], and consequently, a vulnerable implantation.  This hypothesis has been difficult to 
prove as the few studies which have examined the association between maternal caffeine 
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intake, nausea and vomiting in pregnancy and poor pregnancy outcome have produced 
mixed results [10, 20-22]. 
In order to examine the complex relationship between pregnancy outcome, nausea 
and vomiting in pregnancy and caffeine intake, it is clear that a deeper exploration is 
needed.  Inconsistent results from previous studies may be due to a number of 
methodological flaws.  These flaws include an imprecise or biased assessment of caffeine 
exposure, failure to consider changes during pregnancy e.g. changes in intake and 
smoking habits, possible confounders such as alcohol and smoking [23, 24] and 
individual differences in metabolism.    
The Caffeine and Reproductive Health (CARE) study [11] addressed the 
methodological issues described above through a prospective, longitudinal observational 
study of the relationship between maternal caffeine intake, metabolism and fetal growth 
restriction.  The results of this study showed that maternal caffeine consumption 
throughout pregnancy was associated with an increased risk of fetal growth restriction 
and that this association was stronger among women with a faster caffeine metabolism 
than those with a slower caffeine metabolism.  Nausea has been associated with increased 
estrogen levels [4, 25, 26] which in turn have been negatively associated with CYP1A2 
activity, the primary enzyme implicated in caffeine metabolism [25, 27]; therefore nausea 
may have a role to play in the association found in the CARE study.    Indeed, a recent 
review has stressed the importance of examining the ‘pregnancy signal i.e. a reduction to 
coffee consumption and aversion to other odours and tastes [28].  Therefore the results of 
the CARE study warranted further investigation of the relationship between fetal growth 
restriction, nausea and vomiting of pregnancy, maternal caffeine intake and metabolism.  
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Hence our aim here was to use the valuable data collected by the CARE study [11] to 
explore the relationships between nausea and vomiting of pregnancy and (a): fetal growth 
restriction; and (b) maternal caffeine metabolism and fetal growth restriction. 
 
Methods 
 
Participants 
Pregnant women assessed as at low risk of complications were prospectively recruited 
from the maternity units of two large UK teaching hospitals (Leeds and Leicester) from 
September 2003 to June 2006.  Women aged 18-45 years with singleton pregnancies 
were recruited.  Those with prior chronic disease, psychiatric illness, HIV or hepatitis B 
infection were excluded.  Following screening of pre-booking maternity notes, eligible 
women were sent study information and were asked to return a reply slip indicating their 
willingness to take part in the study.  Personal contact was made with those who agreed 
to take part and the initial visit was conducted at the hospital, the volunteer’s general 
practice or home by a clinical research fellow.  The demographic details of the 
participants were recorded by a questionnaire (age, parity, maternal height, weight, 
socio-economic status and gestational age).  Local ethics committee approval was 
obtained at both centres and written informed consent was collected before recruitment. 
 
Measurements 
Caffeine intake 
Detailed methods on the caffeine assessment are described elsewhere [11].  A validated 
caffeine assessment tool (CAT) to record habitual caffeine intake was administered at 
booking (8-12 weeks) by a clinical research fellow or research midwives, and completed 
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by the participants during weeks 13-28, and finally weeks 28 to the end of pregnancy. 
The questionnaire assessed caffeine consumption from all potential dietary sources and 
over the counter medications. Brand names, portion sizes, methods of preparation, and 
quantity and frequency of intake were recorded for different gestational periods so that 
precise caffeine intakes could be estimated using an in-house program [29]. Each CAT 
also collected details of potential confounders like smoking and alcohol intake.   
 
Caffeine metabolism 
Caffeine half-life was assessed from a caffeine challenge test [29] performed within two 
weeks of recruitment.  The participants were required to fast overnight, complete the 
challenge at home the following morning (a drink of 500 mL diet cola, containing 63.5 
mg caffeine ingested over a period of 20 minutes), and avoid any other caffeine 
consumption during the challenge.  Saliva samples were then collected at approximately 
one and five hours post-challenge using a Salivette® (Sarstedt, Aktiengesellschaft & Co., 
Loughborough, UK).  Participants recorded times of sample collection along with details 
of drinks or food consumed during the test period in a questionnaire.  The samples were 
returned in a pre-paid envelope to the corresponding laboratory at Leeds and Leicester, 
where the saliva was isolated from the Salivettes by centrifugation and stored at -80 C.  
At Leicester, saliva samples were sub-aliquotted and sent, on dry ice, to the University of 
Leeds for analysis.  Half-life for caffeine was calculated from salivary caffeine 
concentrations recorded at one and five hours post-challenge.  Saliva samples were also 
used for determining nicotine exposure.  Salivary cotinine concentrations were quantified 
by an enzyme linked immunosorbent assay (ELISA) kit (Cozart Bioscience, Oxfordshire, 
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UK) according to the manufacturer’s instructions in samples taken at recruitment and in a 
sub-sample at 28 weeks gestation (n=488).  Participants were categorized as active 
smokers (>5ng/ml), passive smokers (1-5ng/ml), or non-smokers (<1ng/ml). 
 
Pregnancy details 
For each trimester, participants reported whether they experienced nausea or vomiting 
(yes/no).  Information regarding antenatal pregnancy complications and delivery details 
were obtained from the electronic maternity databases.   Gestational age was dated using 
crown rump length ultrasound measurements performed in the first trimester.  The 
primary outcome measure was fetal growth restriction and has been reported elsewhere 
and in the statistical methods below [11].  
 
Statistical methods 
This analysis examined data collected by the first two CATs (≤28 weeks gestation) so 
that nausea and vomiting in pregnancy during the first and second trimesters could be 
assessed.  The data from the final CAT, which was completed post pregnancy, was not 
used for the current analyses to reduce the influence of recall bias.  Caffeine consumption 
was expressed in mg/day averaged over the individual trimesters and grouped into 
categories of intake (<200mg/day; ≥200mg/day) which are in line with current guidance 
for pregnant women in both the United Kingdom and United States [30, 31]. 
Unconditional logistic regression modelling was used to examine the associations 
between fetal growth restriction, caffeine intake and potential confounding factors, using 
STATA v 10.0 (College Station Texas, USA).  Firstly, the association between fetal 
8 
 
growth restriction and nausea and vomiting of pregnancy was assessed. Fetal growth 
restriction was defined as birthweight below the 10
th
 centile on a customised centile chart 
which incorporated the main non-pathological factors affecting fetal growth - maternal 
height, weight, ethnicity, parity at booking, gestation at delivery and gender of the 
neonates [32].  Ethnicity was categorised as follows: European (includes British Isles and 
those of European origin elsewhere e.g. Australia); Indian; Pakistani; Bangladeshi; Afro-
Caribbean; African (sub-Sahara); Middle Eastern (including North Africa); and South 
East Asian. Parity was defined as the number of times a participant gave birth to a fetus 
with a gestational age of 20 weeks or more.   In addition to the covariates adjusted by the 
use of the customised growth centiles, statistical adjustment was also made in all models 
for salivary cotinine levels and self-reported alcohol consumption assessed at recruitment 
and at 28 weeks, if available. Secondly, we formally tested whether the association 
between fetal growth restriction and maternal caffeine intake differed according to 
experience of nausea and vomiting in pregnancy, by including an interaction term in the 
model and adjusting for smoking, alcohol intake and caffeine half-life.  Finally, we 
repeated the latter analyses examining caffeine half-life rather than caffeine intake 
adjusting for smoking, alcohol, and caffeine intake. Caffeine half-life was not normally 
distributed therefore women were categorised as having a short half-life (fast caffeine 
clearance) or long half-life (slow caffeine clearance) using the median value as a cut-off.  
For this analysis we wished to focus on those with stronger symptoms of pregnancy, 
therefore we assessed nausea and vomiting as a combined symptom (i.e. those who 
experienced both nausea and vomiting - NVP).  However, we also analysed nausea and 
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vomiting in pregnancy separately as both symptoms may occur independently and have 
different aetiologies.   
  
Results 
A total of 13,071 eligible women were invited to participate and 2,643 (20%) consented.  
Eight women were excluded after their pregnancies were terminated.  Of the remaining 
2,635 pregnancies, 2,519 had data on caffeine intake and nausea and vomiting for the 
first and/or second trimester.  Data on caffeine intake and both nausea and vomiting 
(NVP) were not available on all women (1
st
 trimester caffeine intake and NVP (n=1,513); 
2
nd
 trimester caffeine intake and NVP (n=1,583)). Half-life data were available on 1,520 
women.   The median (IQR) for caffeine metabolism half-life was 6.9 (4.5 to 11.7) hours.  
The mean (SD) maternal age was 29.9 (5.9) years.  Just over half of the cohort gave birth 
to boys (n=1269, 52%) and 1191 (48%) women were primiparous.  Thirteen per cent of 
women (n=336) had a growth restricted baby.  The median (IQR) caffeine intake over the 
first and second trimesters was 116.5 (45 to 225) mg/day and 106 (37 to 206) mg/day, 
respectively.  Table 1 presents the number of women who reported nausea and vomiting 
during pregnancy among those who had data on caffeine intake, nausea and vomiting for 
the first and/or second trimester (n=2,519).  Most women experienced nausea during the 
first trimester, with fewer women reporting vomiting.  Almost half (45%) of the women 
reported both nausea and vomiting in pregnancy in the first trimester and 21% in 
trimester two.  
Only the logistic regression analyses conducted on those with stronger symptoms 
(both nausea and vomiting experienced) are presented in this current paper and were 
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conducted among those who had data on caffeine intake, nausea and vomiting for the first 
and/or second trimester (n=2,519).  The logistic regression analyses conducted for nausea 
and vomiting separately produced results similar to the combined analyses and are 
therefore not shown.  Results from logistic regression showed no significant associations 
between fetal growth restriction and nausea and vomiting in pregnancy, even after 
considering the covariates included in the customised growth charts and additional 
adjustment for smoking and alcohol intake (Table 2).  Approximately 70% of women 
who reported nausea and vomiting in the first trimester reported caffeine intakes less than 
200mg/day, with similar results found among those who reported nausea and vomiting in 
the second trimester (Table 3).  Further analyses showed that women who reported 
nausea in the first trimester had significantly lower caffeine intakes compared to those 
who did not (difference: 22 mg/day (95% CI: 6 to 39), p<0.01).  However, there were no 
significant differences in the caffeine intake and fetal growth restriction relationship 
between those experiencing symptoms of nausea and vomiting for either the first 
(p=0.50) or second trimester (p=0.61) and those who did not, after consideration of the 
covariates in the customised growth charts in addition to the adjustment for smoking, 
alcohol intake and caffeine half-life (Table 3).  The models presented in this table 
illustrate the interaction term indirectly. 
Women who experienced nausea and vomiting in pregnancy did not have 
significantly increased odds of having a slow caffeine metabolism after consideration of 
the covariates in the customised growth charts in addition to the adjustment for smoking, 
alcohol, caffeine intake (first trimester nausea and vomiting in pregnancy: OR: 0.87, 95% 
CI:0.67 to 1.13; second trimester nausea and vomiting in pregnancy: OR: 0.84, 95% 
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CI:0.52 to 1.36) .  Table 4 shows that there were no significant differences in the caffeine 
half-life and fetal growth restriction relationship between those experiencing symptoms 
of nausea and vomiting for either the first trimester (p=0.91) or the second trimester 
(p=0.45) and those who did not after consideration of the covariates in the customised 
growth charts in addition to the adjustment for smoking, alcohol intake and caffeine 
intake.    The models presented in this table illustrate the interaction term indirectly. 
 
Discussion 
Main findings 
In our cohort, the incidence of fetal growth restriction (FGR) was 13%, a figure higher 
than that often quoted, however similar to the low birth weight rates reported for the areas 
assessed in this current study[33]. However, it has been shown that using standard birth 
weight measurements for gestational age and gender alone, underestimates growth 
restricted babies by as much as 50% [34].  We therefore believe that our findings reflect 
the true incidence in our population since we used customised charts.  We did not find a 
relationship between nausea and vomiting in pregnancy and fetal growth restriction. 
Although caffeine intake has been implicated in poor pregnancy outcomes [11-15], and in 
this current study, women who experienced nausea in the first trimester had significantly 
lower caffeine intakes, nausea and vomiting did not modify associations between fetal 
growth restriction and maternal caffeine intake or metabolism.    
  
Nausea and vomiting in pregnancy and fetal growth restriction 
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Most of the studies assessing the relationship between nausea and vomiting in pregnancy 
and pregnancy outcome have focussed on spontaneous miscarriage and suggest a 
protective effect of nausea and vomiting in pregnancy [4, 35, 36].  It is however, still well 
recognised that nutrient restriction throughout pregnancy results in fetal growth 
restriction [5].  The Dutch Famine Study [37] suggests that the degree of fetal growth 
restriction is associated with the timing of nutrient restriction. The results from this 
current study do not show any associations between fetal growth restriction and nausea 
and vomiting in pregnancy experienced during the first or second trimester. 
 
Nausea and vomiting in pregnancy, fetal growth restriction and maternal caffeine intake 
To the best of our knowledge, no previous studies have examined if the association 
between maternal caffeine intake and fetal growth restriction differs depending on 
whether the mother experiences nausea and vomiting in pregnancy.  Again, studies have 
tended to explore spontaneous miscarriage as an outcome.  Fenster et al (1991) found an 
association between caffeine intakes >300mg/day and spontaneous miscarriage among 
nauseous women (adjusted OR: 2.10, 95% CI: 1.20 to 3.70), while no association was 
seen among the non-nauseous women [10].  The study by Wen et al (2001) examined the 
associations between maternal caffeine intake and nausea before pregnancy and during 
the first trimester and spontaneous miscarriage [21].  They found that maternal caffeine 
consumption >300mg/day during the first trimester after nausea started might increase 
the risk of spontaneous miscarriage (RR:5.4, 95% CI:2.0 to 14.6), however these results 
were only based on four cases.  On the contrary, Savitz et al  did not find nausea or 
vomiting to be effect modifiers in the relationship between caffeine consumption and 
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spontaneous miscarriage [20].  Similarly, this current study did not find nausea and 
vomiting to modify the association between caffeine intake and fetal growth restriction. 
 
Nausea and vomiting in pregnancy, fetal growth restriction and maternal caffeine 
metabolism 
Although caffeine is commonly consumed during pregnancy, its elimination from the 
blood is slower in pregnant women, probably due to the increased levels of progesterone 
and estrogen [38].  Caffeine concentrations in the fetus are believed to be in equilibrium 
with maternal caffeine concentrations [38],  however caffeine clearance in infants only 
approaches adult values at approximately four and a half months after birth [39].  
Variations in maternal caffeine metabolism have been associated with fetal growth 
restriction [40]. 
 
Nausea has been associated with increased estrogen levels [4, 25, 26] which in turn have 
been negatively associated with CYP1A2 activity, the primary enzyme implicated in 
caffeine metabolism [25, 27].  It may be that the increased risk of spontaneous 
miscarriages found in the studies discussed above [10, 21] was due to decreased caffeine 
metabolism among these women and the subsequent fetal concentrations of this 
xenobiotic.  However results from another study  found that neither estrogen nor 
progesterone altered CYP1A2  levels in 35 pregnant women [41].  In this current study, 
women who experienced nausea and vomiting in pregnancy did not have significantly 
increased odds of having a slow caffeine metabolism after adjusting for smoking, alcohol, 
caffeine intake, mothers age and body mass index.  There was also no significant 
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modification of the relationship between caffeine metabolism and fetal growth restriction 
by symptoms of nausea and vomiting during either the first or second trimesters. 
It is evident from this discussion that many studies investigating the relationship 
between pregnancy symptoms and poor pregnancy outcome, only focus on nausea as the 
symptom and spontaneous miscarriage as the outcome.  It has been suggested that nausea 
in early pregnancy may be associated with a decreased risk of fetal growth restriction, 
however nausea later in pregnancy may be more detrimental to the fetus [5, 8].  This 
study is the first to explore whether nausea and vomiting of pregnancy modifies the 
relationships between fetal growth restriction, maternal caffeine intake and metabolism. 
This current study is not without its limitations however.  Regarding the 
measurements, recall bias may have been introduced as the CATs were completed 
retrospectively, however as the study was primarily examining the effects of caffeine 
intake, it is unlikely that participants underreported their pregnancy symptoms.  The half-
life was measured in the first trimester for some participants and so may not be applicable 
to the second trimester analyses as it has been reported that the caffeine half-life increases 
from approximately 5.6 hours in the first trimester to 8.9 hours between 12 and 20 weeks 
gestation [42].  As the aim of the CAT was to primarily examine the association between 
maternal caffeine intake and fetal growth restriction, our study included a limited 
assessment of self-reported nausea and vomiting in pregnancy which is weakly correlated 
to actual physical symptoms [43].  The CAT did not assess the severity of nausea and 
vomiting of pregnancy; however the CARE study only recruited low-risk pregnant 
women unlikely to have experienced hyperemesis.  This current study did examine 
duration of nausea, however only 17% of the sample experienced nausea and vomiting of 
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pregnancy in both the first and second trimester making it difficult to infer any 
relationship between duration of nausea and vomiting of pregnancy and fetal growth 
restriction.   
Regarding the sample size, the sample sizes calculated for the CARE study were 
not designed to examine interactions. While there was a low response rate, the results 
may not be different from that in the general population as several confounders were 
considered. While the reasons for recruitment decline were not documented due to lack of 
ethical approval to do so, it is thought that parts of this study may have been perceived as 
too invasive hence leading to a low response rate e.g. home visits could take up to one 
hour to complete. The strengths include the detailed assessment of maternal caffeine 
intake and examination of maternal caffeine metabolism, which have been relatively 
unexplored to date [10, 11]. 
The results from our previous analysis of this study showed an association 
between caffeine intake and increased risk of fetal growth restriction, however the results 
from this current analysis show no evidence that this relationship is modified by nausea 
and vomiting in pregnancy. 
A reduction of caffeine intake before and during pregnancy is however, warranted 
to optimise birthweight [11].  Future studies could examine the role of hormones in 
pregnancy outcome and the interaction between nausea and vomiting in pregnancy and 
other pregnancy outcomes. 
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Table 1: Symptoms, caffeine intake, caffeine metabolism, smoking and alcohol intake 
during the first and second trimester 
 
 First trimester Second trimester Both trimesters 
 count % count % count % 
Nausea 2030 81 842 33 769 31 
Vomiting 1188 47 613 24 490 19 
Both nausea and vomiting  1122 45 527 21 426 17 
Caffeine intake (mg/day)       
<200 1744  70 1421 74 - - 
>200 736 30 512 26 - - 
Caffeine metabolism
a
       
Fast - - 765 50 - - 
Slow - - 755 50 - - 
Smokea       
No 1777 74 415 85 - - 
Passive 285 12 17 3 - - 
Yes 339 14 56 12 - - 
Alcohol intake (ml/day??)       
0 581 23 695 36 - - 
0.1-0.5 1127 46 932 48 - - 
≥0.5 772 31 306 16 - - 
a
Few participants took part in the caffeine challenge test during the first trimester (n=4). 
25 
 
b 
Smoking based on salivary cotinine levels: >5ng/ml (smoker), 1-5ng/ml (passive-smoker), <1ng/ml (non-
smoker). Salivary cotinine measurements were taken at recruitment and at 28 weeks gestation.
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Table 2: Unadjusted and adjusted odds ratios for fetal growth restriction according to the 
presence of both nausea and vomiting in pregnancy during the first and second trimestersa 
 
 n (%) Unadjusted 
OR 
(95% 
CI) 
p-
value 
Adjusted 
OR 
(95% 
CI) 
p-
value 
        
Both nausea and 
vomiting during 
first trimester 
1122 
(45%) 
 
0.96 (0.69, 
1.33) 
0.8 0.96 (0.68, 
1.35) 
0.8 
        
Both nausea and 
vomiting during 
second trimester 
527 
(21%) 
 
0.93 (0.69, 
1.25) 
0.6 0.85 (0.53, 
1.35) 
0.5 
a 
Separate models developed for each trimester 
b
Adjusted using the customised growth charts for maternal weight, height, ethnicity, parity, gestational age 
at delivery, sex of baby, and additional adjustment for smoking status (salivary cotinine concentrations) and 
alcohol intake. 
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Table 3: Adjusted odds ratios for fetal growth restriction according to caffeine intake and 
nausea and vomitinga symptoms during pregnancy stratified by trimester 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Presence of both nausea and vomiting 
b
 Adjusted using the customised growth charts for maternal weight, height, ethnicity, parity, gestational age 
at delivery, sex of baby, and additional adjustment for maternal caffeine half-life, smoking status (salivary 
cotinine concentrations) and alcohol intake. 
Caffeine intake (mg/day) n (%) Adjusted OR (95% CI) p-value 
    
1
st
 trimester 1513   
  Without nausea and vomiting    
<200 
≥200              
         
With nausea and vomiting    
<200 
≥200 
401 
266 (66) 
135 (34) 
 
1112 
782 (70) 
330 (30) 
 
1 
0.90 (0.39,2.11) 
 
 
0.86 (0.51, 1.47) 
1.21 (0.52, 2.81) 
 
 
 
 
 
 
0.8 
    
2
nd
 trimester 1583   
  Without nausea and vomiting    
<200 
≥200              
      
With nausea and vomiting   <200 
≥200              
1056 
756 (72) 
258 (24) 
 
527 
369 (70) 
149 (28) 
 
1 
0.95 (0.45,2.01) 
 
 
1.18 (0.62,2.28) 
0.86 (0.30,2.44) 
 
 
 
 
 
 
0.5 
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Table 4: Adjusted odds ratios for fetal growth restriction according to caffeine half life 
and nausea and vomitinga symptoms during pregnancy stratified by trimester 
Caffeine half-life n (%) Adjusted OR (95% CI) p-value 
    
1
st
 trimester 1513   
Without nausea and vomiting    
Shortc 
Longc   
  
With nausea and vomiting    
Short 
Long 
401 
123 (50) 
123 (50) 
 
1112 
325 (51) 
316 (49) 
 
1 
1.18 (0.55,2.55) 
 
 
0.95 (0.49,1.82) 
1.00 (0.53,1.88) 
 
 
 
 
 
 
0.91 
 
 
    
2
nd
 trimester 1583   
 Without nausea and vomiting    
Short 
Long       
 
With nausea and vomiting    
Short 
Long 
1056 
371 (52) 
348 (48) 
 
527 
173 (53) 
154 (47) 
 
1 
1.38 (0.71,2.66) 
 
 
0.85 (0.37,1.95) 
1.31 (0.61,2.81) 
 
 
 
 
 
 
0.45 
a 
Presence of both nausea and vomiting 
b
 Adjusted using the customised growth charts for maternal weight, height, ethnicity, parity, gestational age 
at delivery, sex of baby, and additional adjustment for maternal caffeine intake, smoking status (salivary 
cotinine concentrations) and alcohol intake.  
cShort caffeine half life (≤median value), long half-life ≥median value) 
 
 
 
 
